Showing 1891-1900 of 2150 results for "".
- EU Authorizes First COVID-19 Vaccine With Pfizer, BioNTech’s Comirnatyhttps://modernod.com/news/eu-authorizes-first-covid-19-vaccine-with-pfizer-biontechs-comirnaty/2478691/The European Commission on Monday granted a conditional marketing authorization to Pfizer and BioNTech’s coronavirus vaccine BNT162b2, which will go by the name Comirnaty, with the decision coming mere hours after the Committee for Medicinal Products for Human Use (CHMP) gave its backing fo
- The Cassini Ambient Now Compatible With the Catalys Precision Laser Systemhttps://modernod.com/news/the-cassini-ambient-now-compatible-with-the-catalys-precision-laser-system/2478642/Cassini Technologies announced that the compatibility between the latest cOS 6.0 software for the Catalys Precision Laser System and the Cassini Ambient is ready for market launch. The Cassini Ambient and Catalys Precision Laser System will be jointly promoted as part of a collaboration agreement
- Topcon Announces the US Launch of RDx Telehealth Software Platformhttps://modernod.com/news/topcon-announces-the-us-launch-of-rdx-telehealth-software-platform/2478617/Topcon Healthcare announced that it has launched its new Topcon RDx ocular telehealth software platform in the US market. Topcon RDx is an eye health exam platform that allows practitioners to connect to their office remotely and conduct comprehensive eye exams in real-time from virtual
- Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda in the European Unionhttps://modernod.com/news/aerie-pharmaceuticals-receives-positive-chmp-opinion-for-roclanda-in-the-european-union/2478543/Aerie Pharmaceuticals announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorization application (MAA) for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.0
- Lumenis Launches Digital Duet SLT-YAG Platformhttps://modernod.com/news/lumenis-launches-digital-duet-digital-slt-yag-platform/2478540/Lumenis announced the launch of the Digital Duet SLT-YAG platform. The Digital Duet, which Lumenis describes as the first digital SLT-YAG system on the market, improves glaucoma treatment and posterior capsulotomy with the introduction of advanced digital and connectivity capabilities—rede
- Ocular Therapeutix and AffaMed Therapeutics Announce License Agreement for Dextenza and OTX-TIC in Asiahttps://modernod.com/news/ocular-therapeutix-and-affamed-therapeutics-announce-license-agreement-and-collaboration-for-dextenza-and-otx-tic-in-asia/2478479/Ocular Therapeutix announced a license agreement and a collaboration with AffaMed Therapeutics for the development and commercialization of Dextenza and OTX-TIC in Greater China, South Korea, and the ASEAN markets. Dextenza is currently approved in the U.S. for the treatment of post-surgical ocul
- Samsung Bioepis and Biogen Announce EMA Filing Acceptance of Proposed Lucentis Biosimilarhttps://modernod.com/news/samsung-bioepis-and-biogen-announce-ema-filing-acceptance-of-proposed-lucentis-biosimilar/2478376/Samsung Bioepis and Biogen announced that the European Medicines Agency (EMA) has accepted for review its Marketing Authorization Application for SB11, a proposed biosimilar referencing Lucentis (ranibizumab). Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for retinal vascular d
- Bausch Health Announces Vyzulta Now Approved in Seven Countries; Expanded Coverage in Canadahttps://modernod.com/news/bausch-health-announces-vyzulta-now-approved-in-seven-countries-expanded-coverage-in-canada/2478323/Bausch Health Companies and Nicox announced that Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% has received regulatory approval in Ukraine, bringing the total number of countries where Vyzulta is approved to market to seven. These countries include
- Aerie Pharmaceuticals Announces Interim 90-Day Topline Data From Its 6-Month Mercury 3 Clinical Trial in Europehttps://modernod.com/news/aerie-pharmaceuticals-announces-interim-90-day-topline-data-from-its-6-month-mercury-3-clinical-trial-in-europe/2478321/Aerie Pharmaceuticals announced successful interim 90-day topline data from its 6-month phase 3b clinical trial in Europe known as Mercury 3, comparing Roclanda to Ganfort, according to a company news release. Roclanda is marketed in the United States as Rocklatan (netarsudil and latanopro
- Biomarker Indicating Neurodegeneration Identified in the Eyehttps://modernod.com/news/biomarker-indicating-neurodegeneration-identified-in-the-eye/2478302/A new study led by Boston Medical Center researchers indicates a well-known biomarker that serves as a marker for earlier diagnosis of neurodegenerative diseases is now detectable in the eye. Neurofilament light chain, a protein previously detected in cerebrospinal fluid and blood that is